Year: 2021

WHEAT RIDGE, CO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Torque Lifestyle Brands Inc. (OTC Pink: TQLB) (“Torque” or the “Company”), an emerging leader in the manufacture of active lifestyle sports nutrition and supplements, is pleased to provide an update of the Company’s performance in 2021. “We have achieved clear traction with our recent joint venture ‘Zero Torque Manufacturing LLC’, and we wanted to update shareholders as we continue to build on that momentum,” noted David Lovatt, CEO of Torque. “In our first two months of operations since completing this deal, we have seen not only significant purchase orders, but also impressive revenue being generated from operations throughout 2021.” Since closing on the JV with Zero Day Nutrition, Zero Torque has completed three months of operations under the new structure, has received orders...

HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has completed all the Company’s required tasks in preparation for its planned upcoming regulatory submission for Fexapotide Triflutate for the treatment of BPH.  “Speaking for Management, we are extremely pleased that all the external factors which had caused some moderate delays this past year are behind us at this time.” said Paul Averback, CEO of Nymox. “We hope that our supporters understand that there are many complex parts involved, and these times have seen certain adjustments that we and many other groups have had to handle with some patience. Given the usual seasonal delays, we expect that the formal date that we send the first application in will not...

Highlights:Stimulus funding continues to drive high order rates Material shortages and higher input costs impact third quarter net sales and gross margin Output and shipments accelerating into fiscal fourth quarterTORRANCE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Virco Mfg. Corporation (NASDAQ: VIRC), the largest manufacturer and supplier of movable furniture and equipment to the education market in the United States, today reported financial results for the quarter ended October 31, 2021 (third quarter of fiscal 2022 ending January 31, 2022). Net sales were $57.3 million for the third quarter of fiscal 2022, up slightly from $57.2 million for the same period of the prior fiscal year. Net income was $1.3 million, or $0.08 per diluted share for the third quarter of fiscal 2022, a decline of 70.4%, compared to net income of...

CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE) — Decklar Resources Inc. (TSX-V: DKL) (OTCQX: DLKRF) (FSE: A1U1) (the “Company” or “Decklar”) announces the results of independent reserve evaluations of the Asaramatoru field reserves effective October 31, 2021. The Company’s share of reserves relates to the Risk Finance and Technical Services Agreement (“RFTSA”) with respect to the 51% of the Asaramatoru Field owned by Prime Exploration and Production Limited (“Prime”). Advanced commercial discussions with the owners of the remaining 49% to extend the RFTSA to include their share of the field are ongoing. October 31, 2021 Reserve Highlights of Decklar’s Interest:Decklar’s total gross proved (“1P”) oil reserves in the Asaramatoru field totaled approximately 4.1 million barrels of oil (“bbls”);Decklar’s total gross proved plus...

–  Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 – –  Phase 1 clinical trial expected to initiate in the first half of 2021 – –  Company to host virtual KOL event Wednesday, Dec. 15 at 4:30 p.m. ET – WALTHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of two posters related to its lead liquid tumor candidates TSC-100 and TSC-101. The posters were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. TSC-100 and TSC-101 are TCR-T cell products...

BEVERLY HILLS, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Following a major year of expansion with the recently announced acquisition of Canada’s WOW! Unlimited Media, Inc., and a major stake in Germany’s Your Family Entertainment AG, Genius Brands International, Inc. (“Genius Brands” or the “Company”) (NASDAQ: GNUS) continues to strengthen its global operations and strategy with the appointment of Zrinka Dekic as Chief Financial Officer and Head of Strategy and Mergers and Acquisitions. A Media Snippet accompanying this announcement is available by clicking on the image or link below:Ms. Dekic brings nearly 20 years of entertainment industry and financial markets experience, including corporate strategy, investment banking, investment management and corporate finance at The Walt Disney Company, and before that, Goldman Sachs....

Capricor’s Exosome-based mRNA Vaccine for SARS-CoV-2-In-Vivo Preclinical Data Published in the Journal of Biological Chemistry–-Preclinical Data Demonstrates Strong T-Cell Response for High Conserved N Protein which may Confer Longer Lasting Immunity--Completing Non-Clinical Studies for IND Submission- CAP-1002 – Capricor’s Cell Therapy Program for Severe COVID-19 Patients-Phase 2 Trial Enrollment Complete with 63 Patients Randomized--Data Expected in First Quarter 2022- SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced new updates on its vaccine and therapeutic development programs focused on COVID-19. The...

ATHENS, Greece, Dec. 13, 2021 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today that it provided a notice of redemption to its Series B Preferred Shares (“Preferred Shares”) holders for entire of the outstanding amount at par as per the provisions of the Statement of Designation of the Preferred Shares. The Preferred Shares carried a dividend of 8% per annum until January 2023 increasing to 14% per annum thereafter. The Company will use own funds for the redemption which will take place on or about December 20, 2021. Aristides Pittas, Chairman and CEO of EuroDry commented: “We are very pleased to announce the redemption of the outstanding Series B Preferred Shares at par. This redemption...

Keros Therapeutics will be hosting a conference call and webcast today, December 13, 2021, at 4:01 p.m. ET.LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”), as well as preclinical data on the differentiated mechanism of action of KER-050 and its activity in cytopenia models, at the 63rd American Society of Hematology (“ASH”) Annual Meeting and Exposition, held in person...

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response at ≥90 Million FT516 Cells per Dose; 2 Patients Continue in Complete Response at Median Follow-up of 6.5 Months Outpatient Treatment Regimen Was Well-tolerated; No Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host Disease Dose-expansion Cohorts Initiated at 900 Million FT516 Cells per Dose, including in Patients with Aggressive B-cell Lymphoma Previously Treated with Autologous CAR T-cell Therapy SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics,...